Moderna (MRNA) Touches 52-Week High on Strong Clinical Results [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
Moderna surged to a new 52-week high of $50 on Wednesday, a 16 percent jump, as investors took heart from the strong results of its clinical study for Intismeran Autogene in Combination With KEYTRUDA(R) in patients with high-risk melanoma. At market close, the stock pared gains to end the session just up by 15.84 percent at $49.81 apiece. In an updated report, Moderna Inc. (NASDAQ:MRNA) said that the median five-year follow-up data from the Phase 2b study showed that the therapy reduced death risks of patients by 49 percent as compared to Keytruda alone. Moderna Inc. (NASDAQ:MRNA) and Merck plan to present further data from follow up analyses of primary and secondary endpoints at an upcoming medical meeting. In collaboration with Merck, the Phase 3 clinical trial for adjuvant melanoma (INTerpath-001, NCT05933577) is fully enrolled. Two non-small cell lung cancer (NSCLC) Phase 3 studies—evaluating adjuvant treatment in patients with completely resected NSCLC and adjuvant tre
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.GlobeNewswire
- Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Moderna (NASDAQ:MRNA) had its "underperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Moderna (NASDAQ:MRNA) had its "hold" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Moderna (NASDAQ:MRNA) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $25.00 price target on the stock.MarketBeat
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 2/6/26 - Form SCHEDULE
- 2/5/26 - Form SCHEDULE
- 1/12/26 - Form 8-K
- MRNA's page on the SEC website